FDA approves first treatment for eosinophilic esophagitis
Post-COVID conditions are common among adult survivors
26 May 2022Pioneering study identifies global dynamics of antibiotic resistance
26 May 2022FDA approves first treatment for eosinophilic esophagitis
The U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Dupixent (dupilumab) to treat eosinophilic esophagitis patients 12 years and older.
